Skip to content

Haemodynamic Effects and Complications of Continuous Versus Single-shot Spinal Anaesthesia for HIP Fracture Surgery

A Comparison of Haemodynamic Effects, as Assessed by Cardiac Output Monitoring, and Complications of Continuous Versus Single-Shot Spinal Anaesthesia for Hip-Fracture Surgery in Patients Over 50 Years of Age

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07358299
Acronym
CHIPS
Enrollment
216
Registered
2026-01-22
Start date
2026-01-15
Completion date
2029-11-01
Last updated
2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Spinal, Hip Fractures

Keywords

Continuous spinal anaesthesia, Late side effects of spinal anaesthesia, Haemodynamic stability, Follow-up care after proximal femoral fractures, Quality of life after proximal femoral fractures

Brief summary

This research project aims to identify a safer method of spinal anaesthesia for elderly patients undergoing surgical stabilisation of proximal femoral fractures. The study's primary objective is to compare two spinal anaesthesia techniques: the continuous method (investigational), which allows titration of local anaesthetic doses through a catheter placed in the subarachnoid space, and the conventional single-shot bolus injection. The main hypothesis is that the continuous catheter technique reduces the incidence of intraoperative hypotension and related complications, such as delirium, acute kidney injury, and cardiovascular events. Beyond haemodynamic stability-assessed through advanced continuous monitoring of cardiac output and vascular resistance-the study will evaluate early and late complications, as well as quality of life up to 24 months post-surgery. The project is a prospective, randomised, multicentre clinical trial including at least 216 patients over 50 years of age, randomly assigned to one of the two groups. Proximal femoral fractures are a major and growing global health issue, particularly among geriatric patients with multiple comorbidities. The conventional single-shot spinal anaesthesia, though widely used, carries a high risk of hypotension, potentially leading to delirium, acute kidney injury, stroke, and cardiac events. These complications worsen prognosis, decrease quality of life, and increase mortality. Most existing studies are over two decades old, based on small cohorts and outdated anaesthetic protocols, and lack long-term follow-up data (\>30 days) on neurological outcomes, functional recovery, quality of life, and mortality. Moreover, no modern trials have provided direct, comprehensive comparisons between single-shot and continuous spinal anaesthesia. This project therefore seeks to fill this critical evidence gap through a robust randomised clinical trial. Using precise, continuous measurements of arterial pressure, vascular resistance, and cardiac output, alongside long-term assessments of neurological outcomes, quality of life, and survival, it aims to determine whether continuous spinal anaesthesia offers superior safety and should become the new standard of care for this vulnerable population.

Detailed description

Study Flow Diagram. 1. Measured Variables, Measurement Scales, and Tools: * Orthopedic and Anesthesiological Qualification: Conducted according to the standard of care and existing procedures at the participating hospital. * Baseline Assessment: Performed using the following scales: ASA, Apfel, GCS, RASS, NRS, Bromage, Aldrete, CAM-ICU, and SF-36. * Baseline Neurological Assessment: Covering all neurological endpoints specified in the point 7 * Anesthesia Method (determined by group randomization): 1. Both groups: Ultrasound-guided femoral nerve block with 10 ml of 0.5% ropivacaine. 2. Group 1 (Interventional): Continuous spinal anesthesia with titrated doses of 0.5% hyperbaric bupivacaine via an intrathecal catheter. An initial 1 ml induction dose will be administered, followed by 0.5 ml boluses every 15 minutes to achieve a sensory block to the T12 level. Once the block is established, the anesthetic level will be maintained with titrated doses of 0.5-1 ml approximately every hour. The operating table will be kept in a neutral position. 3. Group 2 (Control): Single-shot spinal anesthesia with a bolus of 0.5% hyperbaric bupivacaine, with the dose adjusted according to the patient's weight and height to achieve a sensory block to the T12 level. The operating table will be kept in a neutral position. 2. Intraoperative Monitoring of Vital Signs: 1. Standard Monitoring: Continuous measurement of heart rate (HR) via ECG and arterial oxygen saturation (SpO2) via pulse oximetry, as well as non-invasive blood pressure (NIBP) measured at 3, 5, and 15-minute intervals. 2. Advanced Monitoring: Continuous invasive blood pressure (IBP); uncalibrated cardiac output (CO) measurement-calibrated with stroke volume (SV) calculated by echocardiography (LVOT x VTI\*); and continuous measurement of stroke volume variation (SVV), pulse pressure variation (PPV), and systemic vascular resistance (SVR) throughout the intraoperative period. * Calculated as the product of the left ventricular outflow tract (LVOT) area and the velocity time integral (VTI), measured in the parasternal long-axis and apical 5-chamber views, respectively. 3. Monitoring in the Post-Anesthesia Care Unit (PACU): 1. Continuation of standard vital signs monitoring (HR, BP, SpO2). 2. Continuation of advanced hemodynamic monitoring if hemodynamic instability requires a continuous vasopressor infusion; patients will be transferred to the ICU if stabilization is not achieved. 3. At discharge from PACU: Assessment using the GCS, RASS, NRS, Aldrete, CAM-ICU, and SF-36 scales, and a neurological assessment covering all endpoints specified in in the point 7 . 4. Monitoring on the Orthopedic Ward: a. At hospital discharge: An SF-36 assessment and a neurological assessment covering all endpoints specified in in the point 7 . 5. Assessment of Other Complications: The incidence of other in-hospital complications will be assessed according to established diagnostic criteria if they are suspected to have occurred. 6. Follow-up: Conducted at 1, 3, 6, 12, and 24 months post-intervention. A telephone interview will be performed to complete the SF-36 scale and conduct a neurological assessment covering all endpoints specified in the point 7 . 7. Complications associated with spinal anesthesia: 1. Postoperative nausea and vomiting (PONV) 2. Hypothermia 3. Total spinal anesthesia 4. Cardiac arrest 5. Bladder dysfunction 6. Back pain 7. Transient neurological symptoms (TNS) 8. Post-dural puncture headache (PDPH) 9. Headache other than PDPH 10. Peripheral nerve palsy 11. Cauda equina syndrome 12. Spinal hematoma or hygroma 13. Intracranial hypotension syndrome 14. Central nervous system infection 15. Other

Interventions

DRUGBupivacaine Spinal 0,5% Heavy - bolus

Group 1 (Control Group) will receive single-shot spinal anesthesia with a bolus of 0.5% hyperbaric bupivacaine, with the dose adjusted according to the patient's weight and height to achieve a sensory block up to the T12 dermatome. The operating table will be kept in a neutral position.

DRUGBupivacaine Spinal 0,5% Heavy - titration

Group 2 (Interventional Group) will receive continuous spinal anesthesia administered via a dedicated intrathecal catheter. An initial induction dose of 1 ml of 0.5% hyperbaric bupivacaine will be administered, followed by titrated boluses of 0.5 ml every 15 minutes until a sensory block to the T12 dermatome is achieved. Once the desired block height is established, the anesthetic level will be maintained by administering titrated doses of 0.5-1 ml approximately every hour. The operating table will be kept in a neutral position.

Sponsors

Centre of Postgraduate Medical Education
Lead SponsorOTHER
Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 50 years, regardless of gender * Diagnosis of a proximal femur fracture * Orthopedic qualification for open reduction and internal fixation of the fracture * Informed consent for the surgical procedure * Informed consent for regional anesthesia, i.e., a central neuraxial block (spinal anesthesia) * Informed consent to participate in the study

Exclusion criteria

* Age \< 50 years, regardless of gender * Refusal to consent to surgical treatment * Refusal to consent to regional anesthesia * Refusal to consent to participate in the study * Inability to provide informed consent * Allergy to local anesthetic agents * Severe congenital or acquired coagulation disorders * Failure to meet the recommended time interval between the last dose of an anticoagulant and central neuraxial blockade, according to the 2022 European Journal of Anaesthesiology (EJA) guidelines * Infection at the block site or a systemic infection (i.e., sepsis, septic shock) * Patients with multiple organ dysfunction syndrome requiring hospitalization in the Intensive Care Unit for stabilization of vital functions * Clinical signs of increased intracranial pressure or suspicion of an intracranial mass on imaging studies * Other contraindications to spinal anesthesia as judged by the qualifying physician

Design outcomes

Primary

MeasureTime frameDescription
Mild hypotensionperiproceduralA comparison of frequency and duration of mild hypotensive episodes, defined as a 20% decrease in systolic arterial pressure (SAP) from the baseline value, between spinal anesthesia administered via catheter-based titration dosing (the investigational method) and single-shot administration (the conventional method)

Secondary

MeasureTime frameDescription
Severe hypotensionperiproceduralA comparison of frequency and duration of severe hypotension episodes, defined as a decrease in systolic arterial pressure (SAP) of 30% from the baseline value
Hypotension associated with organ complicationsperiproceduralComparison of the incidence and duration of hypotensive episodes associated with organ complications, defined as a 50% decrease in mean arterial pressure (MAP) from the baseline value
Advanced hemodynamic measurementsperiproceduralA comparison of the incidence and duration of decrease or increase in the following hemodynamic parameters from their baseline values: cardiac index, CI \[ l/min/m²\] , stroke volume index, SVI \[ml/m²\], stroke volume variation index, SVV \[%\] , pulse pressure variation, PPV \[ %\], and systemic vascular resistance index, SVRI \[ dyn·s·cm-⁵/m²\]. The hemodynamic parameters will be indexed for body surface area
BradycardiaperiproceduralComparison of the incidence and duration of relative and absolute bradycardia, defined respectively as a heart rate (HR) below 60 and 40 beats per minute
Hypotension-related complicationsthrough hospitalisation completion, an average of 1 weekComparison of the risk of hypotension-related complications between the study groups: 1. Delirium 2. Acute kidney injury (AKI)
Length of staythrough hospitalisation completion, an average of 1 weekComparison of the length of stay in the Post-Anesthesia Care Unit (PACU) and Intensive Care Unit (ICU), as well as the total hospital length of stay, between the study groups
Mortality0, 1mth, 3mth, 6mth, 12mth, 24mthComparison of the risk of mortality at 1, 3, 6, 12, and 24 months between the study groups
Complications associated with spinal anesthesia:From admission to the hospital to the end of the 2-year follow-up periodComparison of the risk of complications associated with spinal anesthesia: 1. Postoperative nausea and vomiting (PONV) 2. Decrease in body temperature / Hypothermia 3. Total spinal anesthesia 4. Cardiac arrest 5. Bladder dysfunction 6. Back pain 7. Transient neurological symptoms (TNS) 8. Post-dural puncture headache (PDPH) 9. Headache other than PDPH 10. Peripheral nerve dysfunction 11. Cauda equina syndrome 12. Spinal hematoma or hygroma 13. Intracranial hypotension syndrome 14. Central nervous system infection 15. Other
Cardiovascular eventsthrough hospitalisation completion, an average of 1 weekA comparison of the risk of cardiovascular events (ischemic stroke, acute coronary syndrome) during hospitalization between the study groups
Other complications associated with the studied types of anesthesia0 month, 1 month, 3 month, 6 month, 12 month, 24 monthComparison of the risk of other complications associated with the studied types of anesthesia
Bromage motor blockade scoreperiproceduralComparison of the efficacy of both anesthetic techniques, as measured by the degree of motor blockade using the Bromage scale. Intensity of motor block, Modified Bromage score (Breen TW 1993) 1. Complete block (unable to move feet or knees) 2. Almost complete block (able to move feet only) 3. Partial block (just able to move knees) 4. Detectable weakness of hip flexion while supine (full flexion of knees) 5. No detectable weakness of hip flexion while supine 6. Able to perform partial knee bend
Minimal clinically important difference0 month, 1 month, 3 month, 6 month, 12 month, 24 monthAssessment of the minimal clinically important difference (MCID) for patient-reported outcome measures (PROMs) to determine the value and extent of clinical improvement and the associated level of patient satisfaction

Countries

Poland

Contacts

CONTACTMagdalena Fleming, MD
m.fleming@spskgruca.pl00 48 509 995 408
CONTACTRafał Kamiński, MD, PhD
rkaminski@spskgruca.pl0048 502 775 345
STUDY_CHAIRRafał Kamiński, MD, PhD

Dept of Musculoskeletal Trauma Surg and Orthop, Gruca Orthopaedic and Trauma Teaching Hospital, CMKP

PRINCIPAL_INVESTIGATORMagdalena Fleming, MD

Dept of Anesthesiology, Gruca Orthopaedic and Trauma Teaching Hospital, CMKP

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026